Inspire Medical Systems: Investors Should Sleep Better From Here Onwards

Inspire Medical is expected to experience near-term margin volatility due to the 2025 launch of Inspire V, but the company's growth remains strong and valuations are now more attractive at 4x sales. Concerns about GLP-1 drugs impacting demand are likely overstated, and the author remains optimistic about Inspire's long-term potential given continued growth, profitability, and supportive valuations.

Analysis

Inspire Medical Systems (INSP) is demonstrating continued strong growth, although 2025 is anticipated to be a transition year characterized by near-term margin volatility due to the launch of its new Inspire V device. Current valuations appear more attractive, with shares trading at approximately 4 times sales, a notable discount from historical highs, particularly for a business that is profitable and expanding. Concerns regarding the potential negative impact of GLP-1 drugs on demand for Inspire's therapy are considered largely overstated, as the patient population targeted by GLP-1s generally does not align with ideal candidates for Inspire's treatment. The FDA's recent approval for a new device further supports a positive outlook. Despite expectations of short-term market choppiness, the combination of sustained growth, established profitability, and more supportive valuation metrics underpins an optimistic long-term perspective for the company.

Key Decisions for Investors

• Investors should consider the current valuation at 4x sales as a potentially attractive entry point for a long-term position, given the company's profitability and growth trajectory.
• Monitor the Inspire V launch throughout 2025 and its impact on margins, understanding that this period may present short-term volatility.
• Evaluate personal risk tolerance for near-term margin fluctuations against the company's articulated long-term growth potential and the assessment that GLP-1 drug impact is minimal.